KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.

Caicun Zhou, Xiaorong Dong, Gongyan Chen, Zhehai Wang, Xianghua Wu, Yu Yao, Yiping Zhang, Ying Cheng, Hongming Pan, Xiaodong Zhang, Jiuwei Cui, Lifeng Wang, Xi Chen, Xiaoling Li, Ziping Wang, Qiming Wang, Jianxing He, Mengzhao Wang, Iris Yan, Li Qian, Miao Xu, Xiayu Huang, Chun Sun, Jun Cai, Qiong Wu, Marcus Ballinger, Monika Kaul, Minu K Srivastava

Nat Med 31(7) 2375-2384

PMID40379995
PMCIDPMC12283377
DOI10.1038/s41591-025-03658-y
发表日期2025-05-16
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

After the global approval of atezolizumab plus bevacizumab and chemotherapy as first-line metastatic nonsquamous non-small-cell lung cancer (nsqNSCLC) treatment, the IMpower151 ( NCT04194203 ) trial was conducted in China to address regional differences. Chemotherapy-naive patients with metastatic nsqNSCLC (N = 305) were randomized 1:1 to receive either atezolizumab, bevacizumab, carboplatin and paclitaxel or pemetrexed (ABCPem/Pac; n = 152) or placebo plus bevacizumab, carboplatin and pemetrexed or paclitaxel (BCPem/Pac; n = 153). The primary endpoint was investigator-assessed progression-free survival (INV-PFS); secondary endpoints included subgroup analyses of INV-PFS, independent review facility-assessed PFS, overall survival, and investigator-assessed objective response rate and duration of response per RECIST v.1.1. Most patients (97%) received pemetrexed, and 53% had EGFR+ tumors. Median INV-PFS for ABCPem/Pac versus BCPem/Pac was 9.5 versus 7.1 months (stratified hazard ratio: 0.84; 95% confidence interval: 0.65, 1.09; P = 0.184). INV-PFS across subgroups and independent review facility-assessed PFS were consistent with INV-PFS in the intention-to-treat population. Median overall survival was 20.7 versus 18.7 months in the ABCPem/Pac versus BCPem/Pac arms, respectively (stratified hazard ratio: 0.93; 95% confidence interval: 0.67, 1.28). Confirmed objective response rate with ABCPem/Pac versus BCPem/Pac was 48% versus 50%, respectively; median duration of response was 11.3 versus 8.3 months. Adverse events of special interest for atezolizumab were observed in 68% (grades 3 and 4: 11%) and 71% (grades 3 and 4: 7%) of patients receiving ABCPem/Pac and BCPem/Pac, respectively. The most common adverse events of special interest for atezolizumab in the ABCPem/Pac and BCPem/Pac arms were hepatitis (driven by laboratory abnormalities; mostly low grade), hypothyroidism and rash. Overall, IMpower151 did not meet its primary endpoint (INV-PFS) in metastatic nsqNSCLC. ABCPem/Pac was generally well tolerated, with no new safety signals. Trial registration number: ClinicalTrials.gov, NCT02366143.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Extended Data Fig. 3

OS by EGFR mutation status. Kaplan-Meier curves in patients with ( a ) EGFR mutation and ( b ) EGFR WT. EGFR mutation status was based on the presence of EGFR genomic alterations or ALK rearrangements. Sensitizing EGFR mutations include exon 19 del, L858R, S768I, L861Q, and G719X. ( c ) OS in key patient subgroups of the EGFR mutation group. Data markers in (c) represent HRs, with error bars indicating 95% CIs. a Unstratified HR is reported. b Includes patients with sensitizing EGFR mutations S768I, L861Q and G719X (n = 7). c Two patients in the ABCPem/Pac arm had both sensitizing EGFR mutations exon19 del and L858R. d One patient was wrongly randomized as EGFR WT in the interactive voice- or web-based response system and had received no prior TKI treatment. e Prior lines were counted only when the reason for stopping was disease progression. f One patient with EGFR mutation received EGFR TKI but the reason for stopping was not disease progression. 1G, first generation; 2G, second generation; 3G, third generation; ABCPem/Pac, atezolizumab plus bevacizumab, carboplatin, and pemetrexed or paclitaxel; ALK , anaplastic large-cell lymphoma kinase; BCPem/Pac, placebo plus bevacizumab, carboplatin, and pemetrexed or paclitaxel; CI, confidence interval; EGFR , epidermal growth factor receptor; HR, hazard ratio; NE, not estimable; TKI, tyrosine kinase inhibitor; WT, wild type.

A

OS

Extended Data Fig. 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Extended Data Fig. 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1IMpower151 CONSORT diagram. Patient disposition. ABCPem/Pac, atezolizumab plus bevacizumab, carboplatin and pemetrexed or paclitaxel; BCPem/Pac, placebo plus bevacizumab, carboplatin and pemetrexed or paclitaxel.
非 KM Figure
Fig. 2Investigator-assessed PFS. a , Kaplan–Meier curves in the ITT population. b , Forest plot in key patient subgroups. Data markers in b represent HRs, with error bars indicating 95% CIs. a Stratified log-rank. b Unstratified HR is reported. c Includes patients with ALK WT tumors. d Includes patients with sensitizing EGFR mutations exon 19 del ( n = 96); L858R ( n = 57); S768I, L861Q and G719X ( n = 7); and ALK rearrangement ( n = 5). e Prior lines were counted only when the reason for stopping was disease progression. f One patient with EGFR mutation received EGFR TKI, but the reason for stopping was not disease progression. g One patient was wrongly randomized as EGFR WT in the interactive voice- or web-based response system and had received no prior TKI treatment.
非 KM Figure
Fig. 3Overall survival. a , Kaplan–Meier curves in the ITT population. b , Forest plot of OS in key patient subgroups. Data markers in b represent HRs, with error bars indicating 95% CIs. a Unstratified HR is reported. b Includes patients with ALK WT tumors. c Includes patients with sensitizing EGFR mutations exon 19 del ( n = 96); L858R ( n = 57); S768I, L861Q and G719X ( n = 7); and ALK rearrangement ( n = 5). d Prior lines were counted only when the reason for stopping was disease progression. e One patient with EGFR mutation received EGFR TKI, but the reason for stopping was not disease progression. f One patient was wrongly randomized as EGFR WT in the interactive voice- or web-based response system and had received no prior TKI treatment.
非 KM Figure
Fig. 4RNA sequencing comparison of the EGFR mutation subgroup versus the WT subgroup. a , Volcano plot of differentially expressed genes. The log 2 FC indicates the fold change in the expression level for each gene. Each dot represents one gene. |FC| of 2 and unadjusted P value of 0.01 were used to define genes that are differentially expressed at statistically significant levels. Genes that were significantly up or down regulated were labeled in red. b , Hallmark analysis of differentially expressed genes. The enriched gene sets in the EGFR mutation and WT subgroups were labeled in red and blue, respectively. Asterisks denote the level of statistical significance. c , Gene expression signature analysis. The gene signatures that are expressed at higher levels in the EGFR mutation and WT subgroups were labeled in red and blue, respectively. Asterisks denote the level of statistical significance. All P values reported are two sided. The CAMERA method was used to adjust P values in b and c to account for multiple hypothesis testing. CAF, cancer-associated fibroblast; cDC, conventional dendritic cell; DDR, DNA damage response; EMT, epithelial-to-mesenchymal transition; FC, fold change; MDSC, myeloid-derived suppressor cells; MHC, major histocompatibility complex; Mono_CD14, CD14 + monocytes; Mono_CD16, CD16 + monocytes; NES, normalized enrichment score; Pan_F_TBRS, pan-fibroblast TGF-β response signature; TAM, tumor-associated macrophages; T eff , effector T cell; T H 1, T helper 1 cell; T H 2, T helper 2 cell; T reg , regulatory T cell. Source data
非 KM Figure
Extended Data Fig. 1Investigator-assessed PFS by EGFR mutation status. Kaplan-Meier curves in patients with ( a ) EGFR mutation and ( b ) EGFR WT. EGFR mutation status was based on the presence of EGFR genomic alterations or ALK rearrangements. Sensitizing EGFR mutations include exon 19 del, L858R, S768I, L861Q, and G719X. ( c ) Investigator-assessed PFS in key patient subgroups of the EGFR mutation group. Data markers in (c) represent HRs, with error bars indicating 95% CIs. a Unstratified HR is reported. b Includes patients with sensitizing EGFR mutations S768I, L861Q and G719X (n = 7). c Two patients in the ABCPem/Pac arm had both sensitizing EGFR mutations exon19 del and L858R. d One patient was wrongly randomized as EGFR WT in the interactive voice- or web-based response system and had received no prior TKI treatment. e Prior lines were counted only when the reason for stopping was disease progression. f One patient with EGFR mutation received EGFR TKI but the reason for stopping was not disease progression. 1G, first generation; 2G, second generation; 3G, third generation; ABCPem/Pac, atezolizumab plus bevacizumab, carboplatin, and pemetrexed or paclitaxel; ALK , anaplastic large-cell lymphoma kinase; BCPem/Pac, placebo plus bevacizumab, carboplatin, and pemetrexed or paclitaxel; CI, confidence interval; EGFR , epidermal growth factor receptor; HR, hazard ratio; TKI, tyrosine kinase inhibitor; WT, wild type.
非 KM Figure
Extended Data Fig. 2IRF-assessed PFS. Kaplan-Meier curves in the intention-to-treat population. ABCPem/Pac, atezolizumab plus bevacizumab, carboplatin, and pemetrexed or paclitaxel; BCPem/Pac, placebo plus bevacizumab, carboplatin, and pemetrexed or paclitaxel; CI, confidence interval; HR, hazard ratio; IRF, independent review facility.
非 KM Figure
Extended Data Fig. 4RNA sequencing comparison of patients with long PFS (≥ median) vs short PFS (< median) in the ITT population. ( a ) Volcano plot of differentially expressed genes in the ABCPem/Pac arm. The log 2 FC indicates the fold change in the expression level for each gene. Each dot represents one gene. |FC| of 2 and unadjusted P value of 0.01 were used to define genes that are differentially expressed at statistically significant levels. Genes that were significantly up or down regulated were labeled in red. ( b ) Volcano plot of differentially expressed genes in the BCPem/Pac arm. The log 2 FC indicates the fold-change in the expression level for each gene. Each dot represents one gene. |FC| of 2 and unadjusted P value of 0.01 were used to define genes that are differentially expressed at statistically significant levels. Genes that were significantly up or down regulated were labeled in red. ( c ) Hallmark analysis of differential gene expression in the ABCPem/Pac and BCPem/Pac arms. The enriched gene sets in the long and short PFS subgroups were labeled in red and blue, respectively, for both the ABCPem/Pac and BCPem/Pac arms. Asterisks denote the level of statistical significance. ( d ) Gene expression signature analysis in the ABCPem/Pac and BCPem/Pac arms. The gene signatures that are expressed at higher levels in the long and short PFS subgroups were labeled in red and blue, respectively, for both the ABCPem/Pac and BCPem/Pac arms. Asterisks denote the level of statistical significance. All P values reported are 2 sided. The CAMERA method was used to adjust P values in (c) and (d) to account for multiple hypothesis testing. ABCPem/Pac, atezolizumab plus bevacizumab, carboplatin, and pemetrexed or paclitaxel; BCPem/Pac, placebo plus bevacizumab, carboplatin, and pemetrexed or paclitaxel; CAF, cancer-associated fibroblast; cDC, conventional dendritic cell; DDR, DNA damage response; EGFR , epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; FC, fold change; ITT, intention to treat; MDSC, myeloid-derived suppressor cells; MHC, major histocompatibility complex; Mono_CD14, CD14 + monocytes; Mono_CD16, CD16 + monocytes; NES, normalized enrichment score; Pan_F_TBRS, pan-fibroblast TGF-β response signature; PFS, progression-free survival; TAM, tumor-associated macrophages; T eff , effector T cell; T H 1, T helper 1 cell; T H 2, T helper 2 cell; T reg , regulatory T cell; WT, wild type. Source data
非 KM Figure